Robert Atchinson
CIK 1403404 · last filed 2024-05-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
52ND FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABEO | 10%+ Owner | — | $4.30 | — | $0 | 1 | 2024-05-08 |
| GCM Grosvenor Inc. (GCMGW) Delisted | 10%+ Owner | 4,318,049 | $0.01 | $41.0K | -$18.22M | 2 | 2023-05-10 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | 10%+ Owner | 2,375,000 | — | — | -$106.86M | 1 | 2016-09-16 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 2,539,949 | $38.00 | $96.52M | -$17.34M | 1 | 2015-10-19 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | 10%+ Owner | 5,639,366 | — | — | $47.50M | 1 | 2015-05-04 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | 10%+ Owner | 2,706,592 | — | — | -$167.61M | 9 | 2015-01-09 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 129,184 | $0.00 | $39 | $40.00M | 1 | 2014-10-03 |
| HeartWare International, Inc. (HTWR) Delisted | 10%+ Owner | 1,996,889 | — | — | $38.47M | 1 | 2014-09-16 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 510,147 | $8.37 | $4.27M | $0 | 1 | 2014-02-20 |
| BOULDER BRANDS, INC. (BDBD) Delisted | 10%+ Owner | 6,497,978 | — | — | -$14.93M | 1 | 2013-01-25 |
| Sleep Number Corp (SCSS) Delisted | 10%+ Owner | 5,415,000 | — | — | -$5.45M | 2 | 2011-02-11 |
| Cardiome Pharma Corp (CRME) Delisted | 10%+ Owner | 6,700,000 | — | — | -$45.14M | 2 | 2010-04-16 |
| BOULDER BRANDS, INC. (SMBL) Delisted | 10%+ Owner | 4,480,724 | — | — | $0 | 1 | 2007-12-14 |
Recent Filings · Page 2 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-20 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Conv (C) | +2,477,875 | $0 | EDGAR |
| 2013-09-03 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Disp (D) | −193,000 | -$4.67M | EDGAR |
| 2013-08-28 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Disp (D) | −75,500 | -$1.89M | EDGAR |
| 2013-08-02 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Disp (D) | −900,190 | -$20.81M | EDGAR |
| 2013-01-25 | BOULDER BRANDS, INC. (BDBD) Delisted | Sell (S) | −1,103,415 | -$14.93M | EDGAR |
| 2012-07-27 | — | Buy (P) | +3,020,000 | $37.37M | |
| 2012-07-18 | — | Buy (P) | +765,000 | $8.58M | |
| 2012-04-26 | — | Buy (P) | +500,000 | $7.00M | |
| 2012-04-26 | — | Buy (P) | +1,000,000 | $13.97M | |
| 2012-03-05 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Buy (P) | +1,821,935 | $28.33M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.